Despite concerns about the corona virus in China
the medical group Fresenius expects more profit again. After one
Fresenius wants to have a difficult year in the German hospital business
leave his weak phase behind. So it should
Currency-adjusted sales increase by up to 7 percent in 2020 and the
Gain up to 5 percent like the Dax Corporation
announced. “We firmly believe this year again
To achieve earnings growth, “said CEO Stephan Sturm on
Thursday in Bad Homburg. Last year had the profit
Adjusted for currency stagnation.
The corona virus now provides headwind. Fresenius with the
Divisions Clinics, Liquid Medicines and Infusions (Kabi) as well as the
Dialysis daughter FMC is mainly in Europe and the
USA engaged. However, Kabi has production facilities in China because of
of the new lung disease, said Sturm. The division
‘ll feel the consequences of the corona virus on the volume sold
to get.
Access to hospitals is restricted in the People’s Republic
and supply chains would be disrupted. “There is a lot of inventory
worked, “said Sturm. There were also many precursors for medicines
from China. The longer the virus epidemic, the more
Bottlenecks would be more likely.
The dialysis subsidiary Fresenius Medical Care (FMNC) also had China
declared a growth market. There are most of them worldwide
Dialysis patients, but only 45 percent of the Chinese with chronic
Kidney failure would have access to treatment. The treatments
in the centers continued despite the coronavirus, but there was
problems selling home dialysis equipment. Because of the
Lung diseases keep many Chinese at home.
When the business outlook for the current year, Sturm left
a back door open. There are possible consequences of the corona virus
not included. It was too early to figure them out. Currently awaiting
Fresenius has no significant negative financial impact.
Fresenius, with over 294,000 employees worldwide, has a bumpy job
Year behind. For example, the number of cases in the hospital business decreased,
the trend towards outpatient treatment and stricter regulations
loaded. The group also came in for liquid drugs and infusions
the US under price pressure. Sturm had declared 2019 to be a transition year
and after two profit warnings in a row with a lot of skepticism on the stock exchange
to fight. Now Fresenius shares rose by more than 5 percent.
Last year, group sales rose 8 percent to 35.5
Billion euro. The bottom line grew by 2 percent to 1.9
Billions of euros, without currency effects, stagnated. “This is
not our claim, “said Sturm.
During the dialysis subsidiary Fresenius Medical Care in the fourth quarter
the results with liquid drugs, infusions and
clinical nutrition. The hospital business stabilized
on the other hand. Fresenius is Germany’s largest hospital operator
and last had through his Spanish clinic daughter Quironsalud
bought several homes in Colombia. Even entering one
third European country in the hospital business is conceivable
emphasized Sturm.
Fresenius is well prepared for the future, he said. “That’s why
let’s look ahead confidently and confirm ours
ambitious medium-term goals. “Shareholders should have a higher
Dividend of EUR 0.84 per share received after EUR 0.80 in
Vorjahr./nas/als/DP/jha
ISIN DE0008469008 DE0005785802 DE0005785604
AXC0234 2020-02-20 / 12:41
Copyright dpa-AFX Wirtschaftsnachrichten GmbH. All rights reserved. Redistribution, republication or permanent storage without the express prior consent of dpa-AFX is not permitted.
– ,
